Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
345.10B
Market cap345.10B
Price-Earnings ratio
22.23
Price-Earnings ratio22.23
Dividend yield
2.03%
Dividend yield2.03%
Average volume
2.96M
Average volume2.96M
High today
$162.71
High today$162.71
Low today
$161.77
Low today$161.77
Open price
$162.16
Open price$162.16
Volume
359.76K
Volume359.76K
52 Week high
$162.71
52 Week high$162.71
52 Week low
$97.72
52 Week low$97.72

NVS News

Benzinga 2h
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise

On Friday, Novartis AG (NYSE:NVS) shared final results from the Phase 3 ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropat...

Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise
The Wall Street Journal 9h
Novartis Says Vanrafia Drug Slows Kidney Function Decline

Vanrafia got accelerated approval in the U.S. and China for treating proteinuria in adults with IgAN in 2025. fabrice coffrini/Agence France-Presse/Getty Images...

Novartis Says Vanrafia Drug Slows Kidney Function Decline
TipRanks 19h
Novartis price target raised to CHF 135 from CHF 125 at JPMorgan

JPMorgan raised the firm’s price target on Novartis (NVS) to CHF 135 from CHF 125 and keeps an Overweight rating on the shares. Published first on TheFly – the...

Analyst ratings

48%

of 29 ratings
Buy
37.9%
Hold
48.3%
Sell
13.8%

More NVS News

TipRanks 2d
Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on Novartis AG, with a price target of CHF130.00. Valentine's Da...

TipRanks 3d
Novartis downgraded to Hold from Buy at DZ Bank

DZ Bank analyst Elmar Kraus downgraded Novartis (NVS) to Hold from Buy with a CHF 127 price target Published first on TheFly – the ultimate source for real-tim...

TipRanks 7d
Novartis breaks ground on biomedical research center in San Diego

Novartis (NVS) today broke ground on a new, global Biomedical Research center in San Diego, California. Once operational in 2029, the approximately 466,000-squa...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.